Related Experiment Video

Updated: Jan 9, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.4K

How to treat BRAF mutant metastatic melanoma?

Maria Cristina Sini1, Milena Casula1, Marina Pisano1

  • 1Unit of Cancer Genetics, Institute of Genetic and Biomedical Research (IRGB), National Research Council (CNR), Sassari, Italy.

Personalized Medicine
|December 1, 2025
PubMed

Insights

Targeted therapies, including BRAF and MEK inhibitors, and immune checkpoint inhibitors, have improved outcomes for advanced melanoma patients with BRAF mutations. These treatments offer new hope for aggressive skin cancer.

Area of Science:

  • Oncology
  • Dermatology
  • Cancer Research

Background:

  • Melanoma is an aggressive skin cancer originating from melanocytes.
  • Advanced melanoma often shows resistance to standard treatments.
  • BRAF mutations occur in 40% of cutaneous melanomas, correlating with aggressive disease and brain metastasis.

Purpose of the Study:

  • To review the impact of targeted therapies and immune checkpoint inhibitors on metastatic melanoma.
  • To highlight advancements in treating BRAF-mutated melanoma.

Main Methods:

  • Review of recent clinical studies and therapeutic advancements.
  • Analysis of treatment outcomes for BRAF-mutated melanoma.

Main Results:

  • Targeted therapies (BRAF inhibitors, MEK inhibitors) and immune checkpoint inhibitors have significantly improved response rates.
  • Survival rates in metastatic melanoma patients have been enhanced by these novel treatments.

Conclusions:

  • Targeted therapies and immune checkpoint inhibitors represent a significant breakthrough in managing metastatic melanoma, particularly in patients with BRAF mutations.
  • These therapies offer improved prognoses for patients with advanced, aggressive skin cancer.
Keywords:
BRAFMalignant melanomaadjuvant therapyimmune check-point inhibitorsneoadjuvant therapytarget therapy

More Related Videos

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

3.3K
A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K